Cabaletta Bio, Inc.
CABANext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for CABA. That does not mean none is planned.
Get an email about CABA's next catalysts
Track Cabaletta Bio (CABA) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
0 upcoming, 2 past
No catalysts found.
Market Overview
Stock performance and key metrics
CABA-201
Generalized Myasthenia Gravis (gMG)
CABA-201 following preconditioning with fludarabine and cyclophosphamide
Idiopathic Inflammatory Myopathy
DSG3-CAART
Pemphigus Vulgaris
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
CABA-201 | Phase 3 | Generalized Myasthenia Gravis (gMG) | - | - |
CABA-201 following preconditioning with fludarabine and cyclophosphamide | Phase 3 | Idiopathic Inflammatory Myopathy | - | - |
DSG3-CAART | Phase 2 | Pemphigus Vulgaris | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Cabaletta Bio, Inc.'s drug pipeline?β
CatalystAlert tracks 3 drug candidates in Cabaletta Bio, Inc.'s (CABA) pipeline across Phase 3, Phase 2. Its lead program is CABA-201 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Cabaletta Bio, Inc.'s next FDA catalyst?β
CatalystAlert tracks every upcoming catalyst for Cabaletta Bio, Inc. (CABA) β PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings β each confidence-rated as confirmed, estimated or AI-detected.
How do I track CABA biotech catalysts?β
Add CABA to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Cabaletta Bio, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page β sourced from ClinicalTrials.gov, FDA and SEC filings.
